NCT03190759 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Becker AB, Nelson NA, Simons FE
The pulmonary index. Assessment of a clinical score for asthma. Am J Dis Child. 1984 Jun;138(6):574-6.
Gorelick MH, Stevens MW, Schultz TR, Scribano PV
Performance of a novel clinical score, the Pediatric Asthma Severity Score (PASS), in the evaluation of acute asthma. Acad Emerg Med. 2004 Jan;11(1):10-8.
Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program
The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59(5):469-78. Review.
Smith SR, Baty JD, Hodge D 3rd
Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med. 2002 Feb;9(2):99-104.
van der Windt D
Promises and pitfalls in the evaluation of pediatric asthma scores. J Pediatr. 2000 Dec;137(6):744-6.
Weiss KB, Wagener DK
Changing patterns of asthma mortality. Identifying target populations at high risk. JAMA. 1990 Oct 3;264(13):1683-7.

Assessment of the Severity of Acute Asthma Exacerbation in Children Attending the Emergency Departments to Predict Outcomes by Modified Pulmonary Index Score

Details for clinical trial NCT03190759

Clinical trial NCT03190759 - References